APA (7th ed.) Citation

AK, S., AY, K., S, S., RV, B., MR, P., R, N., . . . JG, B. (2019). Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood cancer journal, 9(2), 17. https://doi.org/10.1038/s41408-019-0178-8

Chicago Style (17th ed.) Citation

AK, Stewart, et al. "Phase I Study of the Anti-FcRH5 Antibody-drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma." Blood Cancer Journal 9, no. 2 (2019): 17. https://doi.org/10.1038/s41408-019-0178-8.

MLA (9th ed.) Citation

AK, Stewart, et al. "Phase I Study of the Anti-FcRH5 Antibody-drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma." Blood Cancer Journal, vol. 9, no. 2, 2019, p. 17, https://doi.org/10.1038/s41408-019-0178-8.